United States · Bill · HR
H.R. 2821 (119th)
FDA Modernization Act 3.0
Introduced
10 April 2025
Last action
—
Status
Received in the Senate.
Sponsors
—
Subjects
Discovery layer
Source updated
20 August 2026
Summary
FDA Modernization Act 3.0 This bill requires the Food and Drug Administration (FDA) to publish an interim final rule implementing a provision of the Consolidated Appropriations Act of 2023 that authorized the use of certain alternatives to animal testing to support investigational use of a new drug. The rule must replace references to animal tests, data, studies, models, and research with references to nonclinical tests, data, studies, models, and research throughout the FDA’s regulations governing investigational new drug applications. The rule must be published within one year of the bill’s enactment, and must take immediate effect as an interim final rule.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
No timeline events have been ingested for this record yet.
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
4 official files
Engrossed in House
Engrossed in House
Engrossed in House · EN · 20 July 2026
Reported in House
Reported in House · EN · 18 June 2026
Introduced in House
Introduced in House · EN · 10 April 2025
Introduced in House
summary · EN · 10 April 2025
Sponsors
No sponsors or actors listed by the source.
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.congress.gov/bill/119th-congress/house-bill/2821
- Open data entity: https://api.congress.gov/v3/bill/119/hr/2821